iBCS: 3. A Biopharmaceutics Classification System for Orally Inhaled Drug Products.

biopharmaceutics inhalation inhalation biopharmaceutics classification system (iBCS) inhaled medicines lung dissolution lung dose lung permeability lung solubility

Journal

Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791

Informations de publication

Date de publication:
07 Dec 2023
Historique:
medline: 7 12 2023
pubmed: 7 12 2023
entrez: 7 12 2023
Statut: aheadofprint

Résumé

In this article, we specify for the first time a quantitative biopharmaceutics classification system for orally inhaled drugs. To date, orally inhaled drug product developers have lacked a biopharmaceutics classification system like the one developed to navigate the development of immediate release of oral medicines. Guideposts for respiratory drug discovery chemists and inhalation product formulators have been elusive and difficult to identify due to the complexity of pulmonary physiology, the intricacies of drug deposition and disposition in the lungs, and the influence of the inhalation delivery device used to deliver the drug as a respirable aerosol. The development of an inhalation biopharmaceutics classification system (iBCS) was an initiative supported by the Product Quality Research Institute (PQRI). The goal of the PQRI iBCS working group was to generate a qualitative biopharmaceutics classification system that can be utilized by inhalation scientists as a "rule of thumb" to identify desirable molecular properties and recognize and manage CMC product development risks based on physicochemical properties of the drug and the deposited lung dose. Herein, we define the iBCS classes quantitatively according to the dose number and permeability. The proposed iBCS was evaluated for its ability to categorize marketed inhaled drugs using data from the literature. The appropriateness of the classification of each drug was assessed based on published development, clinical and nonclinical data, and mechanistic physiologically based biopharmaceutics modeling. The inhaled drug product development challenges for each iBCS classification are discussed and illustrated for different classes of marketed inhaled drugs. Finally, it is recognized that discriminatory laboratory methods to characterize regional lung deposition, dissolution, and permeability will be key to fully realizing the benefits of an iBCS to streamline and derisk inhaled drug development.

Identifiants

pubmed: 38059771
doi: 10.1021/acs.molpharmaceut.3c00685
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Jayne E Hastedt (JE)

JDP Pharma Consulting, San Carlos, California 94070, United States.

Per Bäckman (P)

Emmace Consulting, 223 63 Lund, Sweden.

Antonio Cabal (A)

Eisai, Woodcliff Lake, New Jersey 07677, United States.

Andy Clark (A)

Aerogen Pharma, San Mateo, California 94402, United States.

Carsten Ehrhardt (C)

School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin D02 PN40, Ireland.

Ben Forbes (B)

King's College London, London SE1 9NH, U.K.

Anthony J Hickey (AJ)

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
RTI International, Research Triangle Park, North Carolina 27709, United States.

Guenther Hochhaus (G)

University of Florida, Gainesville, Florida 32611, United States.

Wenlei Jiang (W)

Center for Drug Evaluation and Research, Office of Generic Drugs, Office of Research and Standards, U.S. FDA, Silver Spring, Maryland 20993, United States.

Stavros Kassinos (S)

University of Cyprus, 1678 Nicosia, Cyprus.

Philip J Kuehl (PJ)

Lovelace Biomedical, Albuquerque, New Mexico 87108, United States.

David Prime (D)

Pulmonary Drug Delivery Consultant, Ware Royston, SG8 7ED, U.K.

Yoen-Ju Son (YJ)

Genentech, South San Francisco, California 94080, United States.

Simon Teague (S)

GlaxoSmithKline, Stevenage SG1 2NY, U.K.

Ulrika Tehler (U)

Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, 431 83 Gothenburg, Sweden.

Jennifer Wylie (J)

Merck & Co., Inc., Rahway, New Jersey 07065, United States.

Classifications MeSH